Anna Secher
Director - Scientific Novo Nordisk
Seminars
Wednesday 2nd December 2026
Reverse-Translating Clinical Readouts to Refine the Next Generation of Amylin Therapeutics
3:30 pm
- Compare emerging efficacy, tolerability, titration and discontinuation patterns across selective amylin agonists, balanced agonists and amylin-containing combinations, distinguishing molecule-specific effects from potential class effects
- Interrogate whether current clinical performance supports proposed hypotheses around receptor selectivity, exposure, signalling bias and dose escalation, identifying which mechanistic assumptions require revision
- Translate clinical successes and disappointments back into preclinical decisionmaking, enabling earlier programs to update target product profiles, assays and candidate-selection criteria before entering costly trials
